GlassScriptPhysician profile
William Richard Gray
NPI 1649395229
$5,762.83
in general payments reported to CMS, 2019-2025
42 companies · $1,570 in 2025
The $1,570 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $773 · 2022: $906 · 2023: $1,172 · 2024: $1,341 · 2025: $1,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,083.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,010.91 | 2021-2025 | |
| Abbvie INC. | $750.58 | 2022-2025 | |
| Amgen INC. | $664.48 | 2021-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $356.11 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $342.80 | 2021-2025 | |
| Lilly USA, LLC | $317.80 | 2021-2025 | Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $257.17 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $181.74 | 2023-2025 | Veozah |
| Inspire Medical Systems, INC. | $162.37 | 2024-2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $148.30 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $140.14 | 2021-2025 | Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.02 | 2025 | Xifaxan |
| Shield Therapeutics INC | $108.65 | 2023-2025 | Accrufer |
| Indivior INC. | $106.84 | 2021-2022 | |
| Renalytix Ai, INC. | $85.23 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $72.50 | 2022 | |
| Paratek Pharmaceuticals, INC. | $72.03 | 2021-2022 | |
| Horizon Therapeutics Plc | $66.09 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.05 | 2025 | Jardiance |
| Virtus Pharmaceuticals LLC | $62.87 | 2021 | |
| Incyte Corporation | $55.66 | 2022-2023 | Opzelura |
| Daiichi Sankyo INC. | $53.43 | 2023-2024 | Injectafer |
| Biogen, INC. | $49.92 | 2025 | Skyclarys |
| Axsome Therapeutics, INC. | $47.05 | 2025 | Symbravo |
| Boston Scientific Corporation | $41.12 | 2023 | Avvigo Guidance System |
| Intra-Sana Laboratories | $40.48 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Redhill Biopharma INC. | $40.22 | 2022 | |
| Intuity Medical INC | $37.27 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Medicomp INC | $35.96 | 2025 | Telepatch Cardiac Monitor |
| Allergan, INC. | $35.57 | 2021 | |
| Sanofi Pasteur INC. | $28.27 | 2025 | |
| Procept Biorobotics Corporation | $27.52 | 2023 | Aquabeam Robotic System |
| Teva Pharmaceuticals USA, INC. | $22.08 | 2025 | Austedo Xr |
| Clarus Therapeutics INC. | $21.34 | 2021 | |
| Heartflow, INC. | $21.28 | 2024 | |
| Advanced Oxygen Therapy INC. | $20.28 | 2022 | |
| Philips North America LLC | $20.01 | 2024 | (Ck7) Extended Holter |
| Bioventus LLC | $18.37 | 2023 | Exogen Ultrasound Bone Healing System |
| Endo Pharmaceuticals INC. | $17.47 | 2021 | |
| Hologic Sales and Service, LLC | $15.52 | 2023 | Thinprep 2000 Processor |
| Sebela Pharmaceuticals INC. | $15.07 | 2023 | Pramosone, Naftin |
| Acerus Pharmaceuticals Corporation | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.